PharmaEssentia Beheer

Beheer criteriumcontroles 3/4

De CEO PharmaEssentia is Ko-Chung Lin, benoemd in Jan2017, heeft een ambtstermijn van 7.83 jaar. bezit rechtstreeks 1.73% van de aandelen van het bedrijf, ter waarde $ 100.33M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 3.3 jaar.

Belangrijke informatie

Ko-Chung Lin

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	7.8yrs
Eigendom CEO	1.7%
Management gemiddelde ambtstermijn	5.1yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ko-Chung Lin's beloning veranderd ten opzichte van PharmaEssentia's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	NT$2b
Jun 30 2024	n/a	n/a	NT$1b
Mar 31 2024	n/a	n/a	NT$442m
Dec 31 2023	n/a	n/a	-NT$624m
Sep 30 2023	n/a	n/a	-NT$890m
Jun 30 2023	n/a	n/a	-NT$1b
Mar 31 2023	n/a	n/a	-NT$2b
Dec 31 2022	n/a	n/a	-NT$1b
Sep 30 2022	n/a	n/a	-NT$2b
Jun 30 2022	n/a	n/a	-NT$2b
Mar 31 2022	n/a	n/a	-NT$3b
Dec 31 2021	NT$9m	NT$9m	-NT$3b
Sep 30 2021	n/a	n/a	-NT$3b
Jun 30 2021	n/a	n/a	-NT$3b
Mar 31 2021	n/a	n/a	-NT$2b
Dec 31 2020	NT$9m	NT$9m	-NT$2b
Sep 30 2020	n/a	n/a	-NT$1b
Jun 30 2020	n/a	n/a	-NT$862m
Mar 31 2020	n/a	n/a	-NT$856m
Dec 31 2019	NT$9m	NT$8m	-NT$843m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Ko-Chung redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de Luxembourg markt.

Compensatie versus inkomsten: De vergoeding van Ko-Chung is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ko-Chung Lin

7.8yrs

Tenure

NT$9,389,000

Compensatie

Mr. Ko-Chung Lin, Ph D., is the Founder and Chief Strategy Officer of PharmaEssentia Corporation and has been its Chief Executive Officer since January 01, 2017. He also serves as a Director at PharmaEssen...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ching-Leou Teng	Chairman & Chief Pharmaceutical Officer	12.2yrs	NT$8.49m	1.09% $ 63.1m
Ko-Chung Lin	Founder	7.8yrs	NT$9.39m	1.73% $ 100.3m
Chan-Kou Hwang	President	no data	NT$8.49m	0.61% $ 35.1m
Snow Chang	Accounting Manager & Senior Manager of Finance	9.1yrs	geen gegevens	geen gegevens
Samuel Lin	VP and Head of Business Operations & Strategy	2.8yrs	geen gegevens	geen gegevens
Lih-Ling Lin	Chief Scientific Officer	2.3yrs	geen gegevens	0.010% $ 593.8k
Rachel Lipsitz	VP and Head of Corporate Communications & Advocacy	2.8yrs	geen gegevens	geen gegevens
Roddy Mcilwain	Senior VP and Head of Sales & Marketing	3.8yrs	geen gegevens	geen gegevens
Anjana Pursnani	Senior VP & Head of People	2.8yrs	geen gegevens	geen gegevens
Albert Qin	Chief Medical Officer	7.8yrs	geen gegevens	0.0061% $ 353.5k
Narihisa Miyachi	Head of Japan Medical Affairs	6.3yrs	geen gegevens	geen gegevens
Yen-Tung Luan	Chief Operating Officer of Taichung Plant	6.3yrs	geen gegevens	geen gegevens

5.1yrs

Gemiddelde duur

Ervaren management: Het managementteam van 261280558 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ching-Leou Teng	Chairman & Chief Pharmaceutical Officer	12.2yrs	NT$8.49m	1.09% $ 63.1m
Ko-Chung Lin	Founder	3.3yrs	NT$9.39m	1.73% $ 100.3m
Chan-Kou Hwang	President	9.5yrs	NT$8.49m	0.61% $ 35.1m
Jeffrey R. Williams	Independent Director	less than a year	geen gegevens	geen gegevens
Ching-Tsun Liu	Independent Director	less than a year	geen gegevens	0.13% $ 7.4m
Jinn-Der Chang	Independent Director	10.7yrs	NT$120.00k	0.029% $ 1.7m
Jien-Heh Tien	Independent Director	6.4yrs	NT$120.00k	0.00060% $ 34.8k
Ming-Chuan Hsieh	Independent Director	less than a year	geen gegevens	0.0012% $ 69.6k
Norio Komatsu	Chairperson of Japan	3.5yrs	geen gegevens	geen gegevens
Shen Yi Li	Director	3.3yrs	NT$95.00k	0.24% $ 14.2m
HsuehFang Hsu	Director	less than a year	geen gegevens	geen gegevens
ChenJung Hsiao	Director	less than a year	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 261280558 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

PharmaEssentia Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Pharmaessentia Corporation Announces Appointments to Board of Directors

Pharmaessentia Corporation Announces Changes to Members of Third Audit Committee

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

Recent updates

PharmaEssentia Corporation to Report Q3, 2024 Results on Nov 14, 2024

PharmaEssentia Corporation Announces Positive Recommendation from the DSMB to Continue the Phase III Clinical Trial of Ropeginterferon Alfa-2b for Essential Thrombocythemia (ET)

PharmaEssentia Corporation Announces Taiwan MOHW Approves IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors in Principle

PharmaEssentia Corporation to Report Q2, 2024 Results on Aug 13, 2024

PharmaEssentia Corporation Announces Update on its IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors

Pharmaessentia Corporation Announces Appointments to Board of Directors

Pharmaessentia Corporation Announces Changes to Members of Third Audit Committee

PharmaEssentia Corporation Provides an Update on Submission of P1101 PhaseIII Clinical Study Protocol for Pre-fibrotic/Early PMFor Overt PMF at Low to Intermediate-1 Risk to China NMPA

PharmaEssentia Corporation to Report Q1, 2024 Results on May 13, 2024

PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA

PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia

PharmaEssentia Corporation announced a financing transaction

PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA

PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA

PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia

Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B (P1101) for the Treatment of PV in China

PharmaEssentia Corporation Receives Civil Lawsuit Decision from Middlesex Superior Court for the Commonwealth of Massachusetts

PharmaEssentia Corporation Announces Publication of New Results from A Phase 2 Clinical Study with ropeginterferon Alfa-2B (Marketed as Besremi®) for the Treatment of Patients with Polycythemia Vera (PV)

PharmaEssentia Corp. Announces Submission of New Drug Registration of BESREMi (Ropeginterferon Alfa-2b) for PV in Hong Kong

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur